Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
Our medical group recently published a study in the Journal of Thoracic Disease reporting the surgical experience in six patients with resectable epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) after gefitinib as neoadjuvant therapy (1). The publication of this manuscript has triggered a round of interest and discussion. As discussed in the article (1) and related editorials (2), our research was a retrospective study with limitations, consisting of six pooled cases for the purpose of revealing the procedure of neoadjuvant treatment. In this letter to the editor, we attempt to address several issues that were not revealed in the article due to the article type (1).